Anupam Rama
Stock Analyst at J.P. Morgan
(4.91)
# 241
Out of 4,630 analysts
757
Total ratings
56%
Success rate
25.1%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintained: Buy | $217 | $163.41 | +32.79% | 66 | Aug 6, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $53 → $90 | $61.32 | +46.77% | 20 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintained: Buy | $23 | $13.50 | +70.37% | 31 | Aug 6, 2026 | |
| KOD Kodiak Sciences | Rated: Buy | $56 → $66 | $45.37 | +45.47% | 22 | Aug 3, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Rated: Buy | $72 → $107 | $76.06 | +40.68% | 25 | Jul 29, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $51 | $20.50 | +148.78% | 1 | Jul 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $30 | $45.33 | -33.82% | 3 | Jul 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $72 | $25.91 | +177.88% | 29 | Jul 7, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $17 | $12.06 | +40.96% | 33 | Jun 30, 2026 | |
| CAMP Camp4 Therapeutics | Upgraded: Buy | $9 | $4.24 | +112.26% | 3 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.05 | - | 28 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $3.89 | - | 5 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $42.39 | - | 16 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $81 → $66 | $37.02 | +78.28% | 37 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $69 → $70 | $56.61 | +23.65% | 34 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $23.32 | +15.78% | 21 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $8.39 | +31.11% | 16 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $86 | $32.89 | +161.48% | 32 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $53 | $28.65 | +84.99% | 11 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 → $19 | $16.78 | +13.23% | 63 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $18.41 | +24.93% | 11 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $94 → $100 | $84.48 | +18.37% | 42 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.64 | - | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.26 | - | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.41 | - | 20 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $7 → $12 | $3.46 | +246.82% | 12 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 → $45 | $20.40 | +120.59% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $13.77 | +37.98% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $14.50 | +120.69% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $23.67 | +68.99% | 2 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $7.95 | -24.53% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.16 | n/a | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $204 → $170 | $219.20 | n/a | 14 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $4.08 | n/a | 11 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 → $5 | $8.45 | n/a | 6 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $64 | $76.76 | n/a | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 → $26 | $3.46 | n/a | 6 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $50 → $48 | $32.27 | n/a | 15 | May 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $8 | $104.91 | n/a | 3 | May 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $45 | $145.87 | n/a | 6 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.40 | n/a | 4 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $12 → $13 | $16.93 | n/a | 7 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $52.92 | n/a | 2 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $30 → $37 | $8.82 | n/a | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $6 | $0.000001 | n/a | 8 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $56 → $10 | $13.25 | n/a | 5 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $26.25 | n/a | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $1.84 | n/a | 2 | Jun 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $40.17 | n/a | 9 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $73.31 | n/a | 10 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $147.71 | n/a | 1 | Sep 29, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $20 → $19 | $4.32 | n/a | 10 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $15.96 | n/a | 4 | Jun 15, 2016 |
Neurocrine Biosciences
Aug 6, 2026
Maintained: Buy
Price Target: $217
Current: $163.41
Upside: +32.79%
Travere Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $53 → $90
Current: $61.32
Upside: +46.77%
ORIC Pharmaceuticals
Aug 6, 2026
Maintained: Buy
Price Target: $23
Current: $13.50
Upside: +70.37%
Kodiak Sciences
Aug 3, 2026
Rated: Buy
Price Target: $56 → $66
Current: $45.37
Upside: +45.47%
Kiniksa Pharmaceuticals International,
Jul 29, 2026
Rated: Buy
Price Target: $72 → $107
Current: $76.06
Upside: +40.68%
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $20.50
Upside: +148.78%
First Tracks Biotherapeutics
Jul 9, 2026
Reiterated: Buy
Price Target: $30
Current: $45.33
Upside: -33.82%
Ultragenyx Pharmaceutical
Jul 7, 2026
Maintained: Buy
Price Target: $72
Current: $25.91
Upside: +177.88%
Replimune Group
Jun 30, 2026
Upgraded: Buy
Price Target: $17
Current: $12.06
Upside: +40.96%
Camp4 Therapeutics
Jun 22, 2026
Upgraded: Buy
Price Target: $9
Current: $4.24
Upside: +112.26%
Jun 9, 2026
Maintained: Buy
Price Target: n/a
Current: $12.05
Upside: -
Jun 2, 2026
Downgraded: Sell
Price Target: n/a
Current: $3.89
Upside: -
May 31, 2026
Maintained: Buy
Price Target: n/a
Current: $42.39
Upside: -
May 29, 2026
Maintained: Buy
Price Target: $81 → $66
Current: $37.02
Upside: +78.28%
May 22, 2026
Maintained: Buy
Price Target: $69 → $70
Current: $56.61
Upside: +23.65%
May 22, 2026
Maintained: Buy
Price Target: $27
Current: $23.32
Upside: +15.78%
May 22, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $8.39
Upside: +31.11%
May 22, 2026
Maintained: Buy
Price Target: $90 → $86
Current: $32.89
Upside: +161.48%
May 22, 2026
Maintained: Buy
Price Target: $58 → $53
Current: $28.65
Upside: +84.99%
May 18, 2026
Maintained: Hold
Price Target: $18 → $19
Current: $16.78
Upside: +13.23%
May 13, 2026
Maintained: Buy
Price Target: $23
Current: $18.41
Upside: +24.93%
May 12, 2026
Maintained: Buy
Price Target: $94 → $100
Current: $84.48
Upside: +18.37%
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $1.64
Upside: -
Mar 24, 2026
Maintained: Sell
Price Target: n/a
Current: $1.26
Upside: -
Mar 18, 2026
Maintained: Buy
Price Target: n/a
Current: $5.41
Upside: -
Mar 16, 2026
Upgraded: Buy
Price Target: $7 → $12
Current: $3.46
Upside: +246.82%
Mar 9, 2026
Maintained: Buy
Price Target: $33 → $45
Current: $20.40
Upside: +120.59%
Mar 3, 2026
Maintained: Buy
Price Target: $19
Current: $13.77
Upside: +37.98%
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $14.50
Upside: +120.69%
Dec 18, 2025
Maintained: Buy
Price Target: $40
Current: $23.67
Upside: +68.99%
Nov 18, 2025
Maintained: Sell
Price Target: $6
Current: $7.95
Upside: -24.53%
May 14, 2024
Downgraded: Hold
Price Target: n/a
Current: $16.16
Upside: n/a
Feb 1, 2024
Maintained: Hold
Price Target: $204 → $170
Current: $219.20
Upside: n/a
Dec 22, 2023
Downgraded: Sell
Price Target: n/a
Current: $4.08
Upside: n/a
Aug 15, 2022
Maintained: Hold
Price Target: $27 → $5
Current: $8.45
Upside: n/a
May 11, 2022
Maintained: Buy
Price Target: $55 → $64
Current: $76.76
Upside: n/a
May 11, 2022
Maintained: Buy
Price Target: $31 → $26
Current: $3.46
Upside: n/a
May 10, 2022
Maintained: Hold
Price Target: $50 → $48
Current: $32.27
Upside: n/a
May 10, 2022
Maintained: Buy
Price Target: $9 → $8
Current: $104.91
Upside: n/a
May 6, 2022
Maintained: Buy
Price Target: $51 → $45
Current: $145.87
Upside: n/a
Mar 8, 2022
Downgraded: Hold
Price Target: n/a
Current: $4.40
Upside: n/a
Feb 25, 2022
Maintained: Hold
Price Target: $12 → $13
Current: $16.93
Upside: n/a
Nov 12, 2021
Maintained: Buy
Price Target: $55
Current: $52.92
Upside: n/a
Oct 25, 2021
Upgraded: Hold
Price Target: $30 → $37
Current: $8.82
Upside: n/a
Aug 5, 2021
Upgraded: Buy
Price Target: $6
Current: $0.000001
Upside: n/a
Mar 25, 2021
Downgraded: Sell
Price Target: $56 → $10
Current: $13.25
Upside: n/a
Oct 12, 2020
Initiated Coverage: Buy
Price Target: $27
Current: $26.25
Upside: n/a
Jun 5, 2019
Downgraded: Sell
Price Target: n/a
Current: $1.84
Upside: n/a
Mar 1, 2019
Maintained: Buy
Price Target: $7 → $6
Current: $40.17
Upside: n/a
Nov 16, 2017
Upgraded: Hold
Price Target: n/a
Current: $73.31
Upside: n/a
Sep 29, 2017
Maintained: Hold
Price Target: n/a
Current: $147.71
Upside: n/a
Jul 21, 2017
Downgraded: Hold
Price Target: $20 → $19
Current: $4.32
Upside: n/a
Jun 15, 2016
Maintained: Hold
Price Target: n/a
Current: $15.96
Upside: n/a